CONTACT US
Home > Inhibitors/Agonists> > Thymocartin
85466-18-8-Thymocartin Thymocartin

Thymocartin

For research use only. Not for therapeutic Use.

  • CAT Number: I037276
  • CAS Number: 85466-18-8
  • Molecular Formula: C21H40N8O7
  • Molecular Weight: 516.6
  • Purity: 98%
Inquiry Now
Related Small Molecules: Carzenide     Latozinemab     Nirsevimab    

Thymocartin is (Cat.No:I037276) the 32-35 fragment of the naturally occurring thymic factor (thymopoietin).


Catalog Number I037276
CAS Number 85466-18-8
Synonyms

Thymocartin; RGH 0206; Thymocartinum;

Molecular Formula C21H40N8O7
Purity 98%
Solubility Soluble in DMSO
Appearance Solid powder
Storage Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
IUPAC Name (6S,9S,12S,15S)-1,6-diamino-9-(4-aminobutyl)-12-(carboxymethyl)-1-imino-15-isopropyl-7,10,13-trioxo-2,8,11,14-tetraazahexadecan-16-oic acid
InChI InChI=1S/C21H40N8O7/c1-11(2)16(20(35)36)29-19(34)14(10-15(30)31)28-18(33)13(7-3-4-8-22)27-17(32)12(23)6-5-9-26-21(24)25/h11-14,16H,3-10,22-23H2,1-2H3,(H,27,32)(H,28,33)(H,29,34)(H,30,31)(H,35,36)(H4,24,25,26)/t12-,13-,14-,16-/m0/s1
InChIKey COIXXKVZEXZCLU-YXWQFLTLSA-N
SMILES CC(C)[C@@H](C(O)=O)NC([C@H](CC(O)=O)NC([C@H](CCCCN)NC([C@H](CCCNC(N)=N)N)=O)=O)=O
Reference

1: Schmidt MC, Rubas W, Merkle HP. Nasal epithelial permeation of thymotrinan (TP3) versus thymocartin (TP4): competitive metabolism and self-enhancement. Pharm Res. 2000 Feb;17(2):222-8. PubMed PMID: 10751039.
2: Lang S, Langguth P, Oschmann R, Traving B, Merkle HP. Transport and metabolic pathway of thymocartin (TP4) in excised bovine nasal mucosa. J Pharm Pharmacol. 1996 Nov;48(11):1190-6. PubMed PMID: 8961171.
3: Narayana JL, Huang HN, Wu CJ, Chen JY. Efficacy of the antimicrobial peptide TP4 against Helicobacter pylori infection: in vitro membrane perturbation via micellization and in vivo suppression of host immune responses in a mouse model. Oncotarget. 2015 May 30;6(15):12936-54. PubMed PMID: 26002554; PubMed Central PMCID: PMC4536990.
4: Felder ChB, Blanco-Príeto MJ, Heizmann J, Merkle HP, Gander B. Ultrasonic atomization and subsequent polymer desolvation for peptide and protein microencapsulation into biodegradable polyesters. J Microencapsul. 2003 Sep-Oct;20(5):553-67. PubMed PMID: 12909541.
5: Gazdag M, Mihályfi K, Kemenesné BP, Görög S. [High performance liquid chromatography and capillary electrophoresis investigation of the neww immunostimulant tetrapeptide drug, thymocartin]. Acta Pharm Hung. 1997 Sep;67(5):169-74. Hungarian. PubMed PMID: 9432863.
6: Zhang Y, Feng J, Cui L, Zhang Y, Li W, Li C, Shi N, Chen Y, Kong W. Investigation Into Efficiency of a Novel Glycol Chitosan-Bestatin Conjugate to Protect Thymopoietin Oligopeptides From Enzymatic Degradation. J Pharm Sci. 2016 Feb;105(2):828-837. doi: 10.1002/jps.24567. Epub 2016 Jan 11. PubMed PMID: 26173563.
7: Reithmeier H, Herrmann J, Göpferich A. Lipid microparticles as a parenteral controlled release device for peptides. J Control Release. 2001 Jun 15;73(2-3):339-50. PubMed PMID: 11516510.
8: Lapis K, Timár J, Pápay J, Paku S, Szende B, Ladányi A. Experimental metastasis inhibition by pretreatment of the host. Arch Geschwulstforsch. 1990;60(2):97-102. PubMed PMID: 2111128.
9: Dénes L, Hajós G, Szporny L, Szende B, Lapis K, Sipka S, Szegedi G. The effect of thymopoietin 32-34 (TP3) on suramin-induced inhibition on delayed type hypersensitivity in guinea pigs. Immunol Invest. 1987 Jun;16(4):275-9. PubMed PMID: 3323037.
10: Szende B, Kisfaludy L, Lapis K, Dénes L, Szporny L, Nyéke O, Schön I, Hajós G, Ember J, Constantin M, et al. The effect of TP-5 and its analogs on skin grafts in mice. J Immunopharmacol. 1985;7(1):67-78. PubMed PMID: 3891868.
11: Szendrei GI, Fabian H, Mantsch HH, Lovas S, Nyéki O, Schön I, Otvos L Jr. Aspartate-bond isomerization affects the major conformations of synthetic peptides. Eur J Biochem. 1994 Dec 15;226(3):917-24. Erratum in: Eur J Biochem 1995 Aug 1;231(3):868. PubMed PMID: 7813483.
12: Dénes L, Szende B, Hajós G, Szporny L, Lapis K. Therapeutic possibilities of thymopoietin fragments (TP3 and TP4) based on experimental animal models. Drugs Exp Clin Res. 1987;13(5):279-87. PubMed PMID: 3500029.
13: Heizmann J, Langguth P, Biber A, Oschmann R, Merkle HP, Wolffram S. Enzymatic cleavage of thymopoietin oligopeptides by pancreatic and intestinal brush-border enzymes. Peptides. 1996;17(7):1083-9. PubMed PMID: 8959740.
14: Iván E, Bodrogligeti I, Juhász-Nagy A, Német L, Cholnoky E. Preclinical toxicity studies with two thymopoietin-like peptides. Arch Toxicol Suppl. 1985;8:495-8. PubMed PMID: 3868381.
15: Nagy J, Kapás M. In vitro degradation of thymopoietin32-35 in human, dog and rat plasma. Acta Physiol Hung. 1995;83(1):31-7. PubMed PMID: 7660834.
16: Anderlik P, Szeri I, Bános Z, Barna Z. The course of LCMV infection in euthymic and athymic mice pretreated with immunomodulatory agents. Acta Microbiol Hung. 1992;39(3-4):235-9. PubMed PMID: 1343936.
17: Rajnavölgyi E, Kulics J, Szilágyvári M, Kisfaludy L, Nyéki O, Schön I, Gergely J. The influence of new thymopoietin derivatives on the immune response of inbred mice. Int J Immunopharmacol. 1986;8(2):167-77. PubMed PMID: 3519478.
18: Anderlik P, Bános Z, Szeri I, Barna Z. [Effect of pretreatment with immunomodulating agents on the outcome of lymphocytic choriomeningitis virus infection in athymic (nude) and euthymic mice]. Acta Pharm Hung. 1992 Jul;62(4):167-71. Hungarian. PubMed PMID: 1442095.
19: Anderlik P, Antmann K, Cseh K, Kalabay L. [Role of the thymus and normal microbial flora on plasma fibronectin concentration in mice treated with immunomodulatory drugs]. Acta Pharm Hung. 1996 Jul;66(4):165-9. Hungarian. PubMed PMID: 9082837.

Request a Quote